Health-related quality of life

Clinical Research Methods for Surgeons

Volumn , Issue , 2007, Pages 237-251

  Litwin, Mark S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249278973     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-230-4_13     Document Type: Chapter

References (99)

1. Fayers PM, Jones DR. Measuring and analysing quality of life in cancer clinical trials: a review. Stat Med 1983;2(4):429-446.
2. Feeny DH, Torrance GW. Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples. Med Care 1989;27(3 Suppl.):S190-S204.
3. Sadura A, Pater J, Osoba D, et al. Quality-of-life assessment: patient compliance with questionnaire completion. J Natl Cancer Inst 1992;84(13):1023-1026.
4. Fossa SD. Quality of life after palliative radiotherapy in patients with hormone-resistant prostate cancer: single institution experience. Br J Urol 1994;74(3):345-351.
5. Moinpour CM, Lovato LC. Ensuring the quality of quality of life data: the Southwest Oncology Group experience. Stat Med 1998;17(5-7):641-651.
6. Patrick DL, Erickson P. Assessing health-related quality of life for clinical decision-making. In: Walker SR, Rosser RM, eds. Quality of life assessment: key issues in the 1990s. Dordrecht: Kluwer Academic Publishers, 1993:11-64.
7. Osoba D. Measuring the effect of cancer on quality of life. Boca Raton: CRC Press, 1991.
8. WHO. Constitution of the World Health Organization, basic documents. Geneva: WHO, 1948.
9. Fitzpatrick JM, Kirby RS, Krane RJ, et al. Sexual dysfunction associated with the management of prostate cancer. Eur Urol 1998;33(6):513-522.
10. Chang VT, Thaler HT, Polyak TA, et al. Quality of life and survival: the role of multidimensional symptom assessment. Cancer 1998;83(1):173-179.
11. Cassileth BR, Soloway MS, Vogelzang NJ, et al. Patients' choice of treatment in stage D prostate cancer. Urology 1989;33(5 Suppl.):57-62.
12. Tulsky DS. An introduction to test theory. Oncology (Huntingt) 1990;4(5):43-48.
13. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996;334(13): 835-840.
14. Guyatt GH, Naylor CD, Juniper E, et al. Users' guides to the medical literature. XII. How to use articles about health-related quality of life. Evidence-Based Medicine Working Group. JAMA 1997;277(15): 1232-1237.
15. McSweeny AJ, Creer TL. Health-related quality-of-life assessment in medical care. Dis Mon 1995;41(1):1-71.
16. Aaronson NK. Methodologic issues in assessing the quality of life of cancer patients. Cancer 1991;67 (3 Suppl.):844-850.
17. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 1991;12(4 Suppl.):142S-158S.
18. Adler NE, Epel ES, Castellazzo G, Ickovics JR. Relationship of subjective and objective social status with psychological and physiological functioning: preliminary data in healthy white women. Health Psychol 2000;19(6):586-592.
19. Nelson EC, Landgraf JM, Hays RD, Wasson JH, Kirk JW. The functional status of patients. How can it be measured in physicians' offices? Med Care 1990;28(12):1111-1126.
20. Finlay WM, Lyons E. Methodological issues in interviewing and using self-report questionnaires with people with mental retardation. Psychol Assess 2001;13(3):319-335.
21. Fossa SD, Aaronson NK, Newling D, et al. Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group. Eur J Cancer 1990;26(11-12):1133-1136.
22. Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 1998;159(6):1988-1992.
23. Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988;57(1):109-112.
24. Fossa SD, Moynihan C, Serbouti S. Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I. A descriptive pilot study [see comments]. Support Care Cancer 1996;4(2):118-128.
25. Lampic C, von Essen L, Peterson VW, Larsson G, Sjoden PO. Anxiety and depression in hospitalized patients with cancer: agreement in patient-staff dyads. Cancer Nurs 1996;19(6):419-428.
26. Sneeuw KC, Aaronson NK, Sprangers MA, et al. Value of caregiver ratings in evaluating the quality of life of patients with cancer. J Clin Oncol 1997;15(3):1206-1217.
27. Sprangers MA, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol 1992;45(7):743-760.
28. Kornblith AB, Herr HW, Ofman US, Scher HI, Holland JC. Quality of life of patients with prostate cancer and their spouses: the value of a data base in clinical care. Cancer 1994;73:2791-2802.
29. Testa MA. Parallel perspectives on quality of life during antihypertensive therapy: impact of responder, survey environment, and questionnaire structure. J Cardiovasc Pharmacol 1993;21(Suppl. 2):S18-S25.
30. Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA 2002;287(3):321-328.
31. Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998;16(1):275-283.
32. Herrmann D. Reporting current, past, and changed health status. What we know about distortion. Med Care 1995;33(4 Suppl.):AS89-AS94.
33. Aseltine RH, Jr., Carlson KJ, Fowler FJ, Jr., Barry MJ. Comparing prospective and retrospective measures of treatment outcomes. Med Care 1995;33(4 Suppl.):AS67-AS76.
34. Litwin MS. How to measure survey reliability and validity. Thousand Oaks, CA: Sage Publications, 2002.
35. Sprangers MA, Cull A, Groenvold M, et al. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group. Qual Life Res 1998;7(4):291-300.
36. Collins D. Pretesting survey instruments: an overview of cognitive methods. Qual Life Res 2003;12(3):229-238.
37. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334.
38. Nunnally JC. Psychometric theory. 2nd ed. New York: McGraw-Hill, 1978.
39. Messick S. The once and future issues of validity: assessing the meaning and consequences of measurement. In: Wainer H, Braun HI, eds. Test validity. Hillside, NJ: Lawrence Erlbaum Associates, 1988.
40. Zwinderman AH. The measurement of change of quality of life in clinical trials. Stat Med 1990;9(8):931-942.
41. Olschewski M, Schumacher M. Statistical analysis of quality of life data in cancer clinical trials. Stat Med 1990;9(7):749-763.
42. Sprangers MA. Response-shift bias: a challenge to the assessment of patients' quality of life in cancer clinical trials. Cancer Treat Rev 1996;22(Suppl. A):55-62.
43. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999;15(2):141-155.
44. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41(5):582-592.
45. Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 2004;14(1):73-96.
46. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987;40(2):171-178.
47. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77(4):371-383.
48. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989;27(3 Suppl.):S217-S232.
49. Fossa SD, Woehre H, Kurth KH, et al. Influence of urological morbidity on quality of life in patients with prostate cancer. Eur Urol 1997;31(Suppl. 3):3-8.
50. Kagawa-Singer M, Kassim-Lakha S. A strategy to reduce cross-cultural miscommunication and increase the likelihood of improving health outcomes. Acad Med 2003;78(6):577-587.
51. Sagnier PP, Girman CJ, Garraway M, et al. International comparison of the community prevalence of symptoms of prostatism in four countries. Eur Urol 1996;29(1):15-20.
52. Boyle P. Cultural and linguistic validation of questionnaires for use in international studies: the nine-item BPH-specific quality-of-life scale. Eur Urol 1997;32(Suppl. 2):50-52.
53. Vela Navarrete R, Martin Moreno JM, Calahorra FJ, et al. [Cultural and linguistic validation, in Spanish, of the International Prostatic Symptoms Scale (I-PSS)]. Actas Urol Esp 1994;18(8):841-847.
54. Gill TM, Feinstein AR. A critical appraisal of the quality of quality of life measurements. JAMA 1994;272(8):619-626.
55. Ware JE, Kosinski M, Keller SK. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute, New England Medical Center, 1994.
56. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30(6):473-483.
57. Gandek B, Ware JE, Jr., Aaronson NK, et al. Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998;51(11):1149-1158.
58. Kaplan RM, Bush JW, Berry CC. Health status: types of validity and the index of well-being. Health Serv Res 1976;11(4):478-507.
59. Kaplan RM, Ganiats TG, Sieber WJ, Anderson JP. The Quality of Well-Being Scale: critical similarities and differences with SF-36. Int J Qual Health Care 1998;10(6):509-520.
60. Kaplan RM, Sieber WJ, Ganiats TG. The quality of well-being scale: comparison of the interviewer-administered version with a self-administered questionnaire. Psychol Health 1997;12:783-791.
61. Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychol 1982;1:61-80.
62. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res 1988;23(2):203-235.
63. Anderson JP, Kaplan RM, Berry CC, Bush JW, Rumbaut RG. Interday reliability of function assessment for a health status measure. The Quality of Well-Being scale. Med Care 1989;27(11):1076-1083.
64. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981;19(8):787-805.
65. Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson BS. The sickness impact profile: validation of a health status measure. Med Care 1976;14(1):57-67.
66. Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985;35(273):185-188.
67. McDowell IW, Martini CJ, Waugh W. A method for self-assessment of disability before and after hip replacement operations. BMJ 1978;2(6141):857- 859.
68. Martini CJ, McDowell I. Health status: patient and physician judgments. Health Serv Res 1976;11(4): 508-515.
69. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34(3):220-233.
70. Ware JE, Kosinski M, Keller SD. SF-12: How to score the SF-12 physical and mental health summary scales. Boston, MA: The Health Institute, New England Medical Center, 1995.
71. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998;51(11):1171-1178.
72. Norcross JC, Guadagnoli E, Prochaska JO. Factor structure of the Profile of Mood States (POMS): two partial replications. J Clin Psychol 1984;40(5):1270-1277.
73. Jacobson AF, Weiss BL, Steinbook RM, Brauzer B, Goldstein BJ. The measurement of psychological states by use of factors derived from a combination of items from mood and symptom checklists. J Clin Psychol 1978;34(3):677-685.
74. Cella DF, Jacobsen PB, Orav EJ, et al. A brief POMS measure of distress for cancer patients. J Chronic Dis 1987;40(10):939-942.
75. Albrecht RR, Ewing SJ. Standardizing the administration of the Profile of Mood States (POMS): development of alternative word lists. J Pers Assess 1989;53(1):31-39.
76. Baker F, Denniston M, Zabora J, Polland A, Dudley WN. A POMS short form for cancer patients: psychometric and structural evaluation. Psychooncology 2002;11(4):273-281.
77. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365-376.
78. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11(3):570-579.
79. Schag CA, Ganz PA, Heinrich RL. CAncer Rehabilitation Evaluation System-short form (CARES-SF). A cancer specific rehabilitation and quality of life instrument. Cancer 1991;68(6):1406-1413.
80. Schag CA, Ganz PA, Wing DS, Sim MS, Lee JJ. Quality of life in adult survivors of lung, colon and prostate cancer. Qual Life Res 1994;3(2):127-141.
81. Schag CA, Heinrich RL. Development of a comprehensive quality of life measurement tool: CARES. Oncology (Huntingt) 1990;4(5):135-138.
82. Curran D, Fossa S, Aaronson N, Kiebert G, Keuppens E, Hall R. Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG). Eur J Cancer 1997;33(11):1809-1814.
83. Sprangers MA, Groenvold M, Arraras JI, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996;14(10):2756-2768.
84. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994;5:635-642.
85. Aaronson NK, van Andel G. An international field study of the reliability and validity of the EORTC QLQ-C30 version 3 and a disease-specific questionnaire module (QLQ-PR25) for assessing the quality of life of patients with prostate cancer. Brussels: EORTC Data Center, 2001. (EORTC protocol 15011-30011).
86. Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys 1994;28(4):847-856.
87. Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res 1999;8(3):181-195.
88. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997;15(3):974-986.
89. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997;50(6):920-928.
90. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 2001;19(6):1809-1817.
91. McQuellon RP, Russell GB, Cella DF, et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant 1997;19(4):357-368.
92. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13(2):63-74.
93. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(3 Suppl. 2):13-19.
94. de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990;62(6):1034-1038.
95. Litwin MS, Hays RD, Fink A, et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998;36(7):1002-1012.
96. Krongrad A, Perczek RE, Burke MA, et al. Reliability of Spanish translations of select urological quality of life instruments. J Urol 1997;158(2):493-496.
97. Karakiewicz PI, Kattan MW, Tanguay S, et al. Cross-cultural validation of the UCLA prostate cancer index. Urology 2003;61(2):302-307.
98. Kakehi Y, Kamoto T, Ogawa O, et al. Development of Japanese version of the UCLA Prostate Cancer Index: a pilot validation study. Int J Clin Oncol 2002;7(5):306-311.
99. Korfage IJ, Essink-Bot ML, Madalinska JB, et al. Measuring disease specific quality of life in localized prostate cancer: the Dutch experience. Qual Life Res 2003;12(4):459-464.